LungLifeAI Logo

News & Updates

Our Purpose:
To be a driving force in the early detection of lung cancer.

March 13, 2023

Statement re. Silicon Valley Bank

13 March 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Statement re. Silicon Valley Bank LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB, nor does it have a […]
• Read More
March 7, 2023

Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system

7 March 2023 LungLife AI, Inc. (the “Company” or “LungLife”)  Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics. LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung […]
• Read More
February 27, 2023

Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system

27 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung […]
• Read More
February 20, 2023

Preliminary audited results for year ended 31 December 2022

20 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary audited results for year ended 31 December 2022  LungLife to report financial results for full-year 2022 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its audited preliminary results for the year ended 31 December 2022. Summary and Highlights […]
• Read More
February 8, 2023

Notice of Results

LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2022 on Monday 20 February 2023. Investor presentation Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial […]
• Read More
November 30, 2022

Final Pricing Determination

LungLife AI, Inc. (the “Company” or “LungLife”) Final Pricing Determination Medicare Grants Pricing for LungLife’s LungLB® Early Lung Cancer Diagnostic LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Centers for Medicare & Medicaid Services (“CMS”) has granted a price at $2,030 per test for the LungLB® early […]
• Read More
November 30, 2022

Total Voting Rights

LungLife AI, Inc. (the “Company” or “LungLife”) Total Voting Rights The Company’s total issued share capital consists of 25,485,982 Ordinary Shares of US $0.0001 each ("Ordinary Shares") with one voting right per Ordinary Share. There are no Ordinary Shares held in treasury. The total number of voting rights in the Company is therefore 25,485,982. This […]
• Read More
November 15, 2022

Block Listing Six Monthly Return

15 November 2022 LungLife AI, Inc. ("LungLife" or the "Company")   Block Listing Six Monthly Return    LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six-monthly update on its block listing:   Name of applicant: LungLife AI, Inc. Name of scheme: 2010 Stock Incentive Plan 2020 Stock […]
• Read More
November 7, 2022

Director share purchases

LungLife AI, Inc. (the “Company” or “LungLife”) Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 2 November 2022, Paul Pagano, Chief Executive […]
• Read More

Investor inquiries

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down